Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$27.29 USD
-2.00 (-6.83%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $27.27 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Cartesian Therapeutics, Inc. [RNAC]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Phase 2b Data Release Imminent; 1Q24 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data Mid-2024 a Crucial Inflection Point; Reverse Split; Adjusting PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Astellas Terminates Xork Collaboration; No Impact to Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Descartes-08 Phase 2b Data in Mid-2024; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Manufacturing Facility Should Drive Production Scale; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A New Formula for CAR-T in Autoimmunity; Assuming at Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
|